Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
DIABETOLOGY / RESEARCH LETTER
Persistently low initiation of GLP-1 receptor agonists for weight management in individuals without diabetes in Poland: a major unmet need
1
Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
2
Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland
3
Department of Clinical Research and Development, LUX MED Group, Warsaw, Poland
4
Institute of Medical Sciences, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland
5
Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA
6
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Submission date: 2025-06-24
Final revision date: 2025-08-04
Acceptance date: 2025-08-19
Online publication date: 2025-08-27
Corresponding author
Zbigniew Siudak
Department of Internal Medicine and Cardiology Collegium Medicum , Jan Kochanowski University 19a, IX Wieków Kielc St, 25-516 Kielce, Poland
Department of Internal Medicine and Cardiology Collegium Medicum , Jan Kochanowski University 19a, IX Wieków Kielc St, 25-516 Kielce, Poland
Arch Med Sci 2025;21(4):1636-1640
TOPICS
REFERENCES (22)
1.
Kang YM, Bohula EA, Lincoff AM, et al. Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: a meta-analysis of eleven cardiovascular outcome trials. Diabetes Obes Metab 2025; 27: 4017-21.
2.
Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Intern Med 2025; 178: 199-217.
3.
Tirandi A, Montecucco F, Carbone F, Liberale L. Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease. Pol Arch Intern Med 2024; 134: 16658.
4.
Shi I, Khan SS, Yeh RW, Ho JE, Dahabreh IJ, Kazi DS. Semaglutide eligibility across all current indications for US adults. JAMA Cardiol 2025; 10: 96-8.
5.
Radwan RM, Lee YA, Kotecha P, et al. Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment. Diabetes Obes Metab 2025; 27: 3113-23.
6.
Chetty AK, Khunte M, Chen AS, Jastreboff AM, Krumholz HM, Lu Y. Eligibility for anti-obesity medications among medicare beneficiaries with overweight or obesity. J Gen Intern Med 2025; 40: 1467-9.
7.
Siudak Z, Tkaczyk F, Tomaszewska M, Malinowski KP, Szarpak L, Kowalska-Bobko I. The extent and predictors of off-label use of GLP-1 receptor agonists for weight loss management. Diabetes Obes Metab 2025; 27: 3509-11.
8.
Bahit MC, Gibson M, Kuleta M, et al. Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful? Pol Arch Intern Med 2025; 135: 16987.
9.
Stepaniak U, Micek A, Waśkiewicz A, et al. Prevalence of general and abdominal obesity and overweight among adults in Poland. Results of the WOBASZ II study (2013-2014) and comparison with the WOBASZ study (2003-2005). Pol Arch Med Wewn 2016; 126: 662-71.
10.
Puzianowska-Kuznicka M, Kurylowicz A, Wierucki L, et al. Obesity in Caucasian seniors on the rise: is it truly harmful? Results of the PolSenior2 Study. Nutrients 2022; 14: 4621.
11.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024; 403: 1027-50.
12.
Banach M, Fronczek M, Osadnik T, et al. Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology. Arch Med Sci 2024; 20: 1452-60.
13.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389: 2221-32.
14.
Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab 2025; 27 Suppl 2: 66-88.
15.
Lim CE, Pasternak B, Eliasson B, Ueda P. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia 2025; 68: 1680-95.
16.
Siudak Z, Daniec M, Szarpak Ł, Tomaszewska M, Kozela M, Dziewierz A. Low long-term persistence with GLP-1 receptor agonists treatment: real-world evidence from a large Polish cohort. Diabetes Obes Metab 2025 Jul 7. doi: 10.1111/dom.16590 [in press].
17.
Börchers S, Skibicka KP. GLP-1 and its analogs: does sex matter? Endocrinology 2025; 166: bqae165.
18.
Yang Y, He L, Han S, et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes 2025; 17: e70063.
19.
Zdzierak B, Zasada W, Krawczyk-Ożóg A, et al. Influence of sex on the functional assessment of myocardial ischemia. Kardiol Pol 2023; 81: 895-902.
20.
Razavi AC, Sokolsky M, Blumenthal RS. LDL-cholesterol control in high-risk individuals: an international obstacle and call for earlier combination lipid-lowering therapy. Arch Med Sci 2025; 21: 747-9.
21.
Banach M, Fogacci F, Atanasov AG, et al. A 360° perspective on cardiovascular prevention: the International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE). Arch Med Sci 2025; 21: 711-8.
22.
Krawczyk-Suszek M, Gaweł A, Kleinrok A. Ranking of diseases affecting the health-related quality of life of patients in Poland – a cross-sectional study. Arch Med Sci 2024; 20: 1567-78.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
